Technical Analysis for AQST - Aquestive Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 2.88 | -1.03% | -0.03 |
Earnings due: Jun 20
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Hammer Candlestick | Bullish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | -1.03% | |
| BB Squeeze Ended | Range Expansion | -1.03% | |
| Lower Bollinger Band Touch | Weakness | -1.03% | |
| Bollinger Band Squeeze | Range Contraction | -6.19% |
| Alert | Time |
|---|---|
| Down 5% | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| 1.5x Volume Pace | 1 day ago |
| Down 3% | 1 day ago |
| Fell Below Lower Bollinger Band | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 06/20/2024
Aquestive Therapeutics, Inc. Description
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Disease Drugs Psychoactive Drugs Opioids Epilepsy Amyotrophic Lateral Sclerosis Chloroarenes Seizure Gabaa Receptor Positive Allosteric Modulators Neuroendocrine Tumors Neuroendocrine Tumor Parkinson’s Disease Anaphylaxis Riluzole
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.23 |
| 52 Week Low | 1.2514 |
| Average Volume | 2,219,498 |
| 200-Day Moving Average | 2.63 |
| 50-Day Moving Average | 3.69 |
| 20-Day Moving Average | 3.18 |
| 10-Day Moving Average | 3.07 |
| Average True Range | 0.23 |
| RSI (14) | 34.64 |
| ADX | 24.0 |
| +DI | 11.82 |
| -DI | 29.32 |
| Chandelier Exit (Long, 3 ATRs) | 2.90 |
| Chandelier Exit (Short, 3 ATRs) | 3.43 |
| Upper Bollinger Bands | 3.50 |
| Lower Bollinger Band | 2.86 |
| Percent B (%b) | 0.04 |
| BandWidth | 20.32 |
| MACD Line | -0.21 |
| MACD Signal Line | -0.21 |
| MACD Histogram | 0.0012 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.21 | ||||
| Resistance 3 (R3) | 3.20 | 3.07 | 3.16 | ||
| Resistance 2 (R2) | 3.07 | 2.99 | 3.08 | 3.14 | |
| Resistance 1 (R1) | 2.98 | 2.94 | 2.92 | 2.99 | 3.12 |
| Pivot Point | 2.85 | 2.85 | 2.82 | 2.86 | 2.85 |
| Support 1 (S1) | 2.76 | 2.77 | 2.70 | 2.77 | 2.64 |
| Support 2 (S2) | 2.63 | 2.72 | 2.64 | 2.62 | |
| Support 3 (S3) | 2.54 | 2.63 | 2.61 | ||
| Support 4 (S4) | 2.55 |
